Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT07088718
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tirzepatide — DRUG
    New use of tirzepatide dispensing claim is used as the exposure.
  • Dulaglutide — DRUG
    New use of dulaglutide dispensing claim is used as the reference.

Study Details

Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Key Dates

Start date
Oct 1, 2024
Status verified
Aug 2025
Primary completion
Jul 30, 2025
Completion
Jul 30, 2025

Study Design

Enrollment
44,671 participants (actual)

Arms

  • Arm: Tirzepatide
    Exposure group
  • Arm: Dulaglutide
    Reference group

Primary Outcome Measure

First occurence of MACE (all-cause mortailty, myocardial infarction, or death) [ Time Frame: 1 day after cohort entry date until the first of outcome or censoring, up to 365 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02120-

Find similar trials in Boston, MA

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Brigham and Women's Hospital· Boston, MA

Related Studies